← Patent-cliff monitor small molecule WEGOVY HD SEMAGLUTIDE
Loss of exclusivity February 2041 latest FDA-listed patent expiry
Company NOVO NORDISK INC
Drug detail Brand name WEGOVY HD Active ingredient SEMAGLUTIDE Strength 7.2MG/0.75ML (7.2MG/0.75ML) Dosage form SOLUTION Route SUBCUTANEOUS Modality Small molecule FDA approval March 2026 Marketing status RX
Listed patents Patent Expires Type 11318191 February 2041 product 12029779 October 2038 use U-4418 12551536 October 2038 use U-4418 11752198 August 2038 product 12214017 August 2038 product 10888605 August 2038 product 9764003 June 2033 use U-4418 8129343 December 2031 substance, product
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.